From the Federal University of Minas Gerais, Department of Medicine, Belo Horizonte, Brazil (EMP), Evangelical University of Goias, Department of Medicine, Anápolis, Brazil (VRM), University of Groningen and University Medical Center of Groningen, Department of Anaesthesiology, Groningen, The Netherlands (MGdC, MMRFS), Cardoso Fontes Federal Hospital, Department of Anaesthesiology (TSdN), Federal University of Rio de Janeiro, Department of Medicine, Rio de Janeiro, Brazil (ES), McMaster University & DeGroote School of Medicine, Department of Anaesthesiology, Hamilton, Ontario, Canada (CGJ), and Department of Basic and Applied Medical Sciences, Ghent University, Ghent, Belgium (MMRFS).
Eur J Anaesthesiol. 2024 Oct 1;41(10):738-748. doi: 10.1097/EJA.0000000000002042. Epub 2024 Aug 12.
Elderly patients comprise an increasing proportion of patients undergoing surgery, and they require special attention due to age-related physiological changes. Propofol is the traditional agent for anaesthesia, and recently, remimazolam, a novel ultra-short-acting benzodiazepine, has emerged as an alternative to propofol in general anaesthesia.
We aim to compare remimazolam vs . propofol for general anaesthesia in elderly patients regarding hypotension, induction characteristics, haemodynamics and recovery outcomes.
Meta-analysis with sensitivity and trial sequential analyses (TSA) to assess inconsistencies. Risk ratios and mean differences with 95% confidence intervals (95% CIs) were computed using a random effects model. Subgroups and meta-regression according to anaesthesia methods were also performed.
We systematically searched MEDLINE, Embase and Cochrane for randomised controlled trials (RCTs) up to January 1, 2024.
Patients at least 60 years old, comparing remimazolam vs . propofol for general anaesthesia.
Eleven RCTs (947 patients) were included. Compared with propofol, remimazolam was associated with lower postinduction and intra-operative hypotension (RR 0.41, 95% CI 0.27 to 0.62, P < 0.001) and incidence of bradycardia (risk ratio 0.58, 95% CI 0.34 to 0.98, P = 0.04), with a higher heart rate ( P = 0.01). The incidence of injection pain was lower ( P < 0.001), but remimazolam was associated with a longer time to loss of consciousness ( P < 0.001) and a higher bispectral index at loss of consciousness ( P = 0.04). No differences were found for mean arterial pressure, emergence time, extubation time and incidence of emergence agitation. The TSA was consistent and achieved the required information size for hypotension.
Remimazolam significantly reduced the risk of hypotension, bradycardia and injection pain, despite an increase in the time to loss of consciousness. Remimazolam appears to be an effective and well tolerated alternative to propofol in elderly patients undergoing general anaesthesia.
老年患者在接受手术的患者中所占比例不断增加,由于与年龄相关的生理变化,他们需要特别关注。异丙酚是传统的麻醉剂,而最近,新型超短作用苯二氮䓬类药物 remimazolam 已成为全身麻醉中异丙酚的替代药物。
我们旨在比较 remimazolam 与 propofol 在老年患者全身麻醉中的低血压、诱导特征、血液动力学和恢复结果。
荟萃分析,包括敏感性分析和试验序贯分析(TSA)以评估不一致性。使用随机效应模型计算风险比和均数差值及 95%置信区间(95%CI)。还根据麻醉方法进行了亚组和荟萃回归分析。
我们系统地检索了 MEDLINE、Embase 和 Cochrane 数据库,以获取截至 2024 年 1 月 1 日的随机对照试验(RCTs)。
至少 60 岁的患者,比较 remimazolam 与 propofol 用于全身麻醉。
纳入了 11 项 RCT(947 名患者)。与 propofol 相比,remimazolam 与诱导后和术中低血压发生率较低(RR 0.41,95%CI 0.27 至 0.62,P <0.001)和心动过缓发生率较低(风险比 0.58,95%CI 0.34 至 0.98,P =0.04)相关,心率较高(P =0.01)。注射疼痛发生率较低(P <0.001),但 remimazolam 与意识丧失时间较长相关(P <0.001)和意识丧失时的双谱指数较高(P =0.04)。平均动脉压、苏醒时间、拔管时间和苏醒躁动发生率无差异。TSA 是一致的,并达到了低血压的预期信息大小。
尽管 remimazolam 导致意识丧失时间延长,但 remimazolam 显著降低了低血压、心动过缓和注射疼痛的风险。 remimazolam 似乎是老年患者全身麻醉中一种有效且耐受良好的异丙酚替代药物。